{"pub": "marketwatch", "url": "https://marketwatch.com/story/roche-says-outlook-is-improving-as-revenue-grows-2019-10-16-3103449", "downloaded_at": "2019-10-16 07:27:04.953426+00:00", "title": "Roche says outlook is improving as revenue grows", "language": "en", "text": "Roche Holding AG raised its guidance on Wednesday after reporting that sales rose 9.5% in the period from January to September.\n\nSales in the nine months totaled 46.07 billion Swiss francs ($46.16 billion), up from CHF42.08 billion a year earlier. U.S. sales were particularly strong, rising 17% to CHF20.04 billion.\n\nThe Swiss drugmaker ROG, +0.93% said it now expects high-single-digit sales growth at constant exchange rates in 2019, with core earnings per share increasing in line with sales.\n\nPreviously, the company had guided for mid-to-high-single-digit growth at constant exchange rates.\n\nRoche said a strong performance from multiple sclerosis drug Ocrevus, as well as hemophilia medicine Hemlibra and cancer medicines Tecentriq, Perjeta and Avastin helped to offset declining sales of Herceptin and MabThera/Rituxan, which were hit by competition from closely-resembling drugs.", "description": "The Swiss drugmaker said it now expects high-single-digit sales growth at constant exchange rates in 2019, with core earnings per share increasing in line...", "authors": ["Carlo Martuscelli"], "top_image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "published_at": "2019-10-16"}